Scientific Article
previous document  unige:106546  next document
add to browser collection
Title

Les biomarqueurs du liquide céphalorachidien dans la maladie d’Alzheimer en pratique clinique courante

Authors
Magnin, Eloi
Published in Revue médicale suisse. 2016, vol. 12, no. 515, p. 791-794
Abstract The cerebrospinal fluid levels of amyloid beta 1-42 (Aβ1-42), total tau and tau phosphorylated at threonine 181 (ptau181) are well established biomarkers of cerebral amyloid pathology and tau related neurodegeneration, two hallmarks of Alzheimer's disease. These biomarkers can help to improve diagnostic accuracy and consequent decisions on counseling, support, and therapy of patients with mild cognitive impairment and dementia. The use of biomarkers is part of the proposed new criteria of AD diagnosis. It may be particularly helpful in cases of atypical clinical presentation and uncertain diagnosis, and if an important benefit for the patient is expected. The ongoing development of new biomarkers based on less or non-invasive procedures will allow for a larger use of biomarkers to improve the diagnosis of cognitive impairment.
Keywords Alzheimer Disease/cerebrospinal fluid/diagnosis/therapyAmyloid beta-Peptides/cerebrospinal fluidBiomarkers/cerebrospinal fluidCognitive Therapy/methodsDiagnosis, DifferentialEarly DiagnosisHumansPredictive Value of TestsSensitivity and Specificitytau Proteins/cerebrospinal fluid
Identifiers
PMID: 27276722
Full text
Article (Published version) (542 Kb) - public document Free access
Research group Neuropsychiatrie et Biomarqueurs de la maladie d'Alzheimer (991)
Citation
(ISO format)
MAGNIN, Eloi, POPP, Julius. Les biomarqueurs du liquide céphalorachidien dans la maladie d’Alzheimer en pratique clinique courante. In: Revue médicale suisse, 2016, vol. 12, n° 515, p. 791-794. https://archive-ouverte.unige.ch/unige:106546

42 hits

6 downloads

Update

Deposited on : 2018-07-20

Export document
Format :
Citation style :